Alexandris Dimitrios, Alevizopoulos Nektarios, Marinos Leonidas, Kanellis Georgios, Gakiopoulou Charikleia
Department of Oncology, 69032Evaggelismos Hospital, Athens, Greece.
First Department of Pathology, 68989Medical School of University of Athens, Athens, Greece.
J Oncol Pharm Pract. 2023 Jan;29(1):252-257. doi: 10.1177/10781552221096846. Epub 2022 Apr 27.
Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our knowledge, Lichenoid Drug Eruption (LDE) is recorded in a minority of registries.
To describe an LDE induced case by IM treatment.
Histological Confirmation and promptly dermatological consultation relieved successfully the cutaneous adverse event.
Ongoing expansion of IM usage in a wide spectrum of new indications is more likely to make physicians experience such LDE cutaneous side effects more often. Hence, they should be highly suspicious to early detect these distinct histologic entities, handle these undesired complications and guarantee satisfactory immediate outcomes, avoiding frivolous IM dosage modifications.
甲磺酸伊马替尼（IM）是一种酪氨酸激酶抑制剂，据报道可引起多种不良反应，其中大多数涉及皮肤。非苔藓样IM相关的皮肤反应已有充分记录。据我们所知，苔藓样药疹（LDE）仅在少数病例中被记录。
描述1例由IM治疗引起的LDE。
组织学确诊并及时进行皮肤科会诊成功缓解了皮肤不良事件。
IM在广泛的新适应症中的持续应用增加，可能会使医生更频繁地遇到此类LDE皮肤副作用。因此，他们应高度怀疑，以便早期发现这些独特的组织学病变，处理这些不良并发症并确保获得满意的即时疗效，避免轻率地调整IM剂量。
